WHO Supports Access to Affordable Weight-Loss Medications and Promotes Generic Alternatives
WHO recommends key weight-loss medications for global use and urges the production of affordable generic versions to improve access in developing countries, aiming to combat obesity and related health issues worldwide.
The World Health Organization (WHO) has recommended several prominent weight-loss medications for global use, emphasizing the importance of making these drugs accessible in developing countries through affordable generic options. For the first time, WHO has added certain GLP-1 receptor agonists, including semaglutide—found in medications like Ozempic and Wegovy—and tirzepatide, used in Eli Lilly’s Mounjaro, to its list of essential medicines for adults worldwide.
These drugs have gained widespread popularity for their effectiveness in promoting significant weight loss, particularly among individuals with obesity or related health issues. Over 3.7 million deaths in 2021 were linked to overweight and obesity-related illnesses, surpassing the combined toll of infectious diseases such as malaria, tuberculosis, and HIV.
Despite their potential to save lives, the high costs associated with GLP-1 medications—sometimes exceeding $1,000 per month in the U.S.—pose a significant barrier to access in poorer nations. In response, WHO is advocating for increased generic competition to reduce prices and expand availability. Research indicates that generic versions, especially semaglutide produced in India, could be mass-produced at around $4 per month, potentially transforming global access.
Experts like pharmacology researcher Andrew Hill have urged pharmaceutical companies such as Novo Nordisk and Eli Lilly to prioritize global distribution at affordable prices. The patents for semaglutide are set to expire in countries like Canada, India, and China next year, opening the door for more generic producers.
Originally developed to treat diabetes, GLP-1 drugs have shown promise in addressing other health challenges, including addiction. Recent studies suggest they may also reduce risks of hospitalization and premature death among patients with heart conditions.
With more than 800 million people living with diabetes and one in eight worldwide classified as obese, expanding access to these life-saving medications could significantly impact global health. Additionally, WHO is including a range of cancer drugs in its essential list, underscoring its focus on broad healthcare improvements.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Strategies to Protect and Enhance Global Cancer Research Amid Funding Challenges
A comprehensive analysis highlights the urgent need to safeguard and expand global cancer research funding, especially for lower-income countries, to combat rising cancer rates worldwide amidst declining investments.
Progress and Challenges in Reducing Life Expectancy Gaps Across Australia
Recent research shows Australian efforts to narrow socioeconomic disparities in life expectancy are making progress, but regional inequalities still pose significant health challenges. Learn about the latest findings and their implications for public health policy.
Guidelines for Offering Preventive Mastectomy to High-Risk Women
New research indicates that extending preventive mastectomy to women with a higher lifetime risk of breast cancer can significantly reduce disease incidence, supported by cost-effectiveness analyses.
Innovative 3D Cat Heart Models Enhance Understanding of Blood Clot Risks and Reduce Animal Testing
New 3D reconstructions of feline hearts offer vital insights into blood clot formation, helping to improve diagnostics and reduce animal testing while drawing parallels to human heart conditions.